Latest News - Genentech

Monday, April 17, 2017 | FDA Approval/Clearance, Retina, Genentech

FDA Approves Lucentis for All Forms of Diabetic Retinopathy

Genentech announced that the FDA has approved Lucentis (ranibizumab) 0.3 mg for the monthly treatment of all forms of diabetic retinopathy. With this approval, Lucentis becomes the first and only FDA-…

Read the full story

Tuesday, April 04, 2017 | Clinical Trials, Genentech

Genentech Presents Positive Phase 3 Results for Giant Cell Arteritis

Genentech presented for the first time its results from GiACTA, a phase 3 study which evaluated Actemra (tocilizumab) in people with giant cell arteritis (GCA), to an ophthalmology audience. The abstr…

Read the full story

Thursday, February 02, 2017 | Clinical Trials, AMD, Genentech

Genentech Completes Patient Enrollment in Two Large Phase 3 Studies for Lampalizumab

Genentech has completed enrollment in two large phase 3 clinical trials, Chroma and Spectri, investigating the efficacy and safety of lampalizumab in reducing the progression of geographic atrophy (GA…

Read the full story

Monday, January 30, 2017 | Product Releases, AMD, Genentech

Lucentis 0.5 mg Prefilled Syringe Now Available to Order in the US

Ophthalmologists across the United States can now order the Lucentis 0.5 mg prefilled syringe (PFS). The PFS is a new method of administering Lucentis to treat people with wet age-related macular dege…

Read the full story

Tuesday, January 24, 2017 | Clinical Trials, Genentech

FDA Grants Priority Review for Genentech’s Actemra Supplemental Biologics License Application for Giant Cell Arteritis

Genentech announced that the FDA has accepted the company’s supplemental biologics license application for Actemra (tocilizumab) for the treatment of giant cell arteritis (GCA). The FDA also gra…

Read the full story

Thursday, January 05, 2017 | FDA Approval/Clearance, Genentech

FDA Approves Lucentis for Myopic Choroidal Neovascularization

Genentech announced that the FDA has approved Lucentis (ranibizumab) 0.5 mg for the treatment of patients with myopic choroidal neovascularization (mCNV). Lucentis is the first FDA-approved anti-vascu…

Read the full story

Monday, November 14, 2016 | Medical Studies, Genentech

Phase 3 Study Shows Genentech's Actemra is Superior to Steroids Alone in Maintaining Steroid-Free Remission for People with Giant Cell Arteritis

Genentech announced positive results from the phase 3 GiACTA study, which evaluated Actemra (tocilizumab) in people with giant cell arteritis (GCA), according to a company news release. GiACTA met …

Read the full story

Friday, October 14, 2016 | Product Releases, Genentech

FDA Approves Genentech’s Lucentis (Ranibizumab) Prefilled Syringe

Genentech announced that the FDA approved the Lucentis (ranibizumab) 0.5 mg prefilled syringe (PFS) as a new method of administering the medicine. Like the Lucentis 0.5 mg vial, the 0.5 mg PFS is appr…

Read the full story

Tuesday, October 11, 2016 | Clinical Trials, Retina, Genentech

FDA Grants Priority Review to Genentech’s Lucentis Supplemental Biologics License Application for Myopic Choroidal Neovascularization

Genentech announced that the FDA has accepted a supplemental Biologics License Application (sBLA) and granted priority review for Lucentis (ranibizumab) for the treatment of myopic choroidal neovascul…

Read the full story

Wednesday, October 05, 2016 | Clinical Trials, Genentech

FDA Grants Breakthrough Therapy Designation for Actemra in Giant Cell Arteritis

Genentech announced today that the FDA has granted breakthrough therapy designation status to Actemra (tocilizumab) for giant cell arteritis (GCA), a chronic, potentially life-threatening autoimmune c…

Read the full story

Wednesday, June 08, 2016 | Clinical Trials, Genentech

Phase 3 Study Shows Genentech's Actemra (Tocilizumab) Maintained Steroid-Free Remission in People with Giant Cell Arteritis

Genentech announced positive results from the phase 3 study known as GiACTA, which evaluated Actemra (tocilizumab) in people with giant cell arteritis (GCA), according to a company news release. The s…

Read the full story

Monday, May 02, 2016 | Medical Studies, Retina, Genentech

Five-Year Outcomes of CATT Study Comparing Anti-VEGF Agents for Treatment of AMD Released

The National Eye Institute’s CATT (Comparison of Age-related Macular Degeneration Treatments Trial) study was a 2-year study that compared the relative safety and effectiveness of Lucentis (rani…

Read the full story

Sunday, February 28, 2016 | Clinical Trials, Retina, Genentech, Regeneron Pharmaceuticals

Protocol T: 2-Year Data Released

All three anti-VEGF agents evaluated in the Diabetic Retinopathy Clinical Research Network (DRCR.net) Protocol T trial were effective in treating diabetic macular edema (DME) at 2 years, according to …

Read the full story

Wednesday, November 18, 2015 | Earnings & Financials, Retina, Genentech, Ophthotech, Roche

Genentech Elects to Exercise Its Right to Opt-in to the Novartis Portion of the Ophthotech/Novartis Ex-US Agreement for Fovista to Treat Wet AMD

Ophthotech announced that Genentech has elected to exercise its option to participate in the financial arrangements relating to Novartis’ rights under the Ophthotech/Novartis ex-US agreement for…

Read the full story

Friday, November 13, 2015 | Medical Studies, Genentech

DRCR.net: Lucentis Effective for Proliferative Diabetic Retinopathy

A clinical trial funded by the National Institutes of Health has found that the drug ranibizumab (Lucentis) is highly effective in treating proliferative diabetic retinopathy, according to a National …

Read the full story
Load More